Affiliation:
1. Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences Nagoya Japan
2. Department of Dermatology Tokyo Medical University Tokyo Japan
3. Department of Dermatology Fukuoka University Faculty of Medicine Fukuoka Japan
4. Department of Dermatology Teikyo University School of Medicine Tokyo Japan
5. Kojinkai Sapporo Skin Clinic Sapporo Japan
6. Putnam Associates London UK
7. Department of Dermatology Jichi Medical University Tochigi Japan
Abstract
AbstractOur objective was to establish consensus on (1) which patients with plaque psoriasis and limited skin involvement (body surface area [BSA] <10%) are suitable for systemic treatment, and (2) a definition of ‘topical therapy failure’. A steering committee refined 13 statements drawn from literature related to the study objectives. An independent panel of 45 clinical experts from Japan indicated their agreement to each statement using a 10‐point Likert scale (Round 1; strong consensus, ≥70% of responses = 7–10 and median value ≥8). The steering committee reviewed Round 1 results and refined the statements for Round 2, as necessary. In Round 2, the panel indicated their agreement to each statement using a 3‐point scale (strong consensus, ≥70% of responses and median value of 3) and were shown Round 1 responses before voting. Forty‐five clinicians participated in Round 1 and 41 of those (91%) participated in Round 2. Consensus was achieved on the criteria of eligibility for systemic treatment among patients with limited skin involvement as disease involvement at special or difficult to treat areas, psoriasis‐induced psychological distress, uncontrolled symptoms (e.g., scaling, bleeding, pruritus, insomnia) affecting their social life, psoriatic arthritis, or failure of topical therapy. Consensus on criteria for topical failure were persistent symptoms (e.g., itchiness, pain) and plaques, poor patient satisfaction with treatment, a need to increase medication quantity or application time after treatment with two topicals for 4 weeks; or if the Psoriasis Area Severity Index score of >3 or Physician Global Assessment Score of ≥2 after 8 weeks treatment. Our Delphi panel proposes criteria to help physicians identify patients with psoriasis and limited skin involvement who would benefit from systemic therapy and suggests a definition for topical therapy ‘failure’ which could indicate a move to systemic treatment is warranted.